Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9806124 | 0.93 | CYP1A2 (0.58) | CYP1A2CYP2C9ALDH1A1KDM4EMAPK1 | |
| SCHEMBL7135046 | 0.90 | CYP1A2 (0.54) | CYP1A2CYP2C9ALDH1A1KDM4EPKM | |
| SCHEMBL5484470 | 0.89 | CYP1A2 (0.63) | CYP1A2CYP2C9ALDH1A1TSHRHSD17B10 | |
| SCHEMBL335424 | 0.84 | CYP1A2 (0.61) | CYP1A2CYP2C9ALDH1A1KDM4EMAPK1 | |
| SCHEMBL10752281 | 0.84 | CYP1A2 (0.58) | CYP1A2CYP2C9ALDH1A1KDM4EMAPK1 | |
| P-Xylene SCHEMBL3752326 | 0.83 | CYP1A2 (0.70) | CYP1A2CYP2C9ALDH1A1MAPK1TSHR | |
| SCHEMBL3459786 | 0.83 | CYP1A2 (0.65) | CYP1A2CYP2C9ALDH1A1KDM4EMAPK1 | |
| SCHEMBL9436866 | 0.83 | CYP1A2 (0.59) | CYP1A2CYP2C9ALDH1A1KDM4EMAPK1 | |
| SCHEMBL4015131 | 0.82 | CYP1A2 (0.61) | CYP1A2CYP2C9ALDH1A1TSHRHSD17B10 | |
| SCHEMBL11217225 | 0.82 | CYP1A2 (0.58) | CYP1A2CYP2C9ALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0340605-A2 | Ruthenium complexes containing a DNA or RNA sequence | F. HOFFMANN-LA ROCHE AG (CH) | 1989-11-08 | — | — | EP | claimed |
| US-20180201930-A1 | COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS | IONIS PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-9845468-B2 | Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845467-B2 | Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160194638-A1 | COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS | IONIS PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160194637-A1 | COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS | IONIS PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-9192697-B2 | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis | HEMOTEQ AG (DE) | 2015-11-24 | — | — | US | disclosed |
| US-8597720-B2 | Medical product for treating stenosis of body passages and for preventing threatening restenosis | HEMOTEQ AG (DE) | 2013-12-03 | — | — | US | disclosed |
| WO-2012027033-A1 | COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110287169-A1 | MEDICAL PRODUCT FOR TREATING STENOSIS OF BODY PASSAGES AND FOR PREVENTING THREATENING RESTENOSIS | HEMOTEQ AG | 2011-11-24 | — | — | US | disclosed |
| EP-0650960-B1 | Substituted heterocyclic carboxylic acid amide esters, their preparation and their us as medicaments | HOECHST AG (DE) | 1997-03-05 | — | — | EP | disclosed |
| EP-0650961-B1 | Substituted heterocyclic carboxylic acid amides, their preparation, and their use as medicaments | HOECHST AG (DE) | 1997-03-05 | — | — | EP | disclosed |
| EP-0650961-A1 | Substituted heterocyclic carboxylic acid amides, their preparation, and their use as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-03 | — | — | EP | disclosed |
| EP-0650960-A1 | Substituted heterocyclic carboxylic acid amide esters, their preparation and their us as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-03 | — | — | EP | disclosed |
| EP-0439036-A2 | Energy transferring system | F. HOFFMANN-LA ROCHE AG (CH) | 1991-07-31 | — | — | EP | disclosed |
| EP-0178450-B1 | METAL COMPLEXES TO WHICH AN IMMUNOLOGICALLY ACTIVE MATERIAL CAN BE OR IS COUPLED, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 1991-04-17 | — | — | EP | disclosed |
| EP-0340605-A2 | Ruthenium complexes containing a DNA or RNA sequence | F. HOFFMANN-LA ROCHE AG (CH) | 1989-11-08 | — | — | EP | disclosed |
| EP-0132732-B1 | HOMOLOGUES FROM APROTININE WHOSE LYS 15 AMINO ACID IS SUBSTITUTED BY OTHER AMINO ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BAYER AG (DE) | 1988-06-08 | — | — | EP | disclosed |
| EP-0178450-A2 | Metal complexes to which an immunologically active material can be or is coupled, their preparation and use | F. HOFFMANN-LA ROCHE AG (CH) | 1986-04-23 | — | — | EP | disclosed |
| EP-0127797-A1 | Labelled molecules for fluorescence immunoassays and processes and intermediates for their preparation | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-12-12 | — | — | EP | disclosed |